A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas

Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis

(2018) Alona Zer et al.   CANCER TREATMENT REVIEWS

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

(2017) Beatrice Seddon et al.   LANCET ONCOLOGY

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

(2017) William D Tap et al.   LANCET ONCOLOGY

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

(2016) A. López-Pousa et al.   Clinical & Translational Oncology

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

(2016) Javier Martin-Broto et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting

(2016) Alona Zer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial

(2016) Annika Karch et al.   Trials

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

(2015) B. Bui-Nguyen et al.   EUROPEAN JOURNAL OF CANCER

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

(2015) Sant P. Chawla et al.   JAMA Oncology

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

(2014) Jean-Yves Blay et al.   EUROPEAN JOURNAL OF CANCER

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

(2013) H. Gelderblom et al.   EUROPEAN JOURNAL OF CANCER

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

(2012) George D. Demetri et al.   EUROPEAN JOURNAL OF CANCER

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas

(2009) Joan Maurel et al.   JOURNAL OF CLINICAL ONCOLOGY